Showing 4731-4740 of 7112 results for "".
- Dr. Miriam Bettencourt Speaks on Measles Resurgence and the Dermatologist’s Rolehttps://practicaldermatology.com/news/dr-miriam-bettencourt-speaks-on-measles-resurgence-and-the-dermatologists-role/2486877/As the ominous music from the “Mission Impossible” movies played over the speakers, a dramatic voice spoke: “Good morning, doctors. Sixty years of safe and effective vaccine has resulted in the eradication of measles. Recently, however, a distrust of science has pr
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://practicaldermatology.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- Acquisition Broadens Newmedical’s Scar Care and Skincare Platformhttps://practicaldermatology.com/news/strategic-acquisition-broadens-newmedicals-scar-care-and-skincare-platform/2486628/Newmedical Technology, Inc. announced its acquisition of Derma Made®, marking a strategic expansion of its dermatology and aesthetics portfolio, according to a news release from the company. The transaction will meld Newmedica
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://practicaldermatology.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- Prospective Data Show Comparable Performance Between AI and Dermatologistshttps://practicaldermatology.com/news/prospective-data-show-comparable-performance-between-ai-and-dermatologists/2486375/A new systematic review and meta-analysis of prospective studies suggests artificial intelligence (AI) systems can achieve diagnostic performance comparable to dermatologists in melanoma detection using dermoscopy. Investigato
- Oral Melatonin Shows Benefits for Pruritus, Sleep, and QoL in ADhttps://practicaldermatology.com/news/oral-melatonin-shows-benefits-for-pruritus-sleep-and-qol-in-ad/2485982/Melatonin supplementation significantly improved disease severity and several patient-reported outcomes in adults with mild to moderate atopic de
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac